Leo Pharma brings hair loss cream into phase II
Dermatology firm Leo Pharma has begun a phase IIa trial of delgocitinib against the hair loss condition frontal fibrosing alopecia.
by ulrich quistgaard, translated by daniel pedersen
A new clinical study will assess the safety and efficacy of Leo Pharma’s drug candidate delgocitinib in treating the hair loss condition known as frontal fibrosing alopecia, according to a registration on database Clinical Trials.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Small molecules to lead Leo Pharma to greatness
For subscribers
Leo Pharma enters collaboration with Canadian biotech firm
For subscribers
.jpg&w=384&q=75)
